The presence of innovations in all business processes is highly demanded

On April 17, the press service of the Darnytsia company published an important statement of the head of the Darnytsia Group's Board of Directors. The ambitious innovator Dmytro Shymkiv declared that any company that does not engage in innovations is potentially dead in our time. It has no future, as well as no natural impetus to development. By explaining it perfectly, innovations mean relevance. It is a time of unprecedented change that we are experiencing now. As a result, what may have helped an organization succeed previously now could be the reason for its failure or full-stop. Companies have to adapt as it means to evolve in order to correspond to the ever-changing needs of customers.

«The global pharmaceutical industry is striving to adapt. Therefore, it is accelerating the speed of innovation processes exponentially. It is primarily due to fast-reacting production and the development of high technologies. As a result, medicine is becoming more affordable for consumers.» — a top manager in the field of information technology said at the Innovation Day conference of the European Business Association. If necessary, a recording of the discussion can be found on the YouTube EBA as it was published.

He also stressed that Moderna, the company that developed the COVID-19 cure, succeeded in sequencing Matrix RNA in record time. Even though the company went to this for a long time, the process was carried out in the shortest possible time.

Moderna sequenced the vaccine's mRNA in just two days. Thanks to the competent implementation of new technologies, the first stage was completed very fast. In addition, the vaccine can be modified as needed.

Like many other companies, the Ukrainian Darnytsia has adapted the necessary technologies in both areas to develop medicines and business. Doing so will lead to lower therapeutics costs for consumers.

The Ukrainian pharmaceutical company pays special attention to the creation of generics with proven bioequivalence to the original drugs. These are combination drug innovations. Such a drug will replace ten tablets taken three pelves a day with only one. It is just one of many innovation processes. Innovations participate in the development of the company, allowing you to stay relevant.

Anyway, the press service reported that Darnytsia annually allocates more than 10% of the total gross revenue to the development process and research activities, which is more than 235 million euros.